Roche collaborates with Blueprint Medicines to bring a new treatment to people with RET-altered cancers

Roche will obtain co-development and co-commercialisation rights for pralsetinib, an investigational, precision therapy in late-stage development for people with RET-altered non-small cell lung cancer, various types of thyroid cancer and other solid tumours.Blueprint Medicines and Roche will collaborate on the development of pralsetinib.Roche and Blueprint Medicines will co-commercialise pralsetinib in the US while Roche will be responsible for commercial activities outside the US, excluding Greater China*.Roche will pay an upfront of $675 million in cash in addition to a $100 million equity investment in Blueprint Medicines who is eligible to receive up to $927 million in potential milestones, plus royalties on net product sales outside the US.             
Basel, 14 July 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) and Blueprint Medicines Corporation (NASDAQ:BPMC), today announced the signing of a licensing and collaboration agreement providing exclusive rights to Roche for global co-development and commercialisation outside the United States (US), excluding Greater China*. In the US, Genentech, a member of the Roche Group, will obtain co-commercialisation rights to pralsetinib, Blueprint Medicine’s investigational, once-daily oral precision therapy for the treatment of people with RET-altered non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and other types of thyroid cancer, as well as other solid tumours. In addition, pralsetinib has demonstrated tumour-agnostic potential. The companies also plan to expand development of pralsetinib in multiple treatment settings and explore development of a next-generation RET inhibitor under the collaboration.Attachment14072020_MR_ Roche collaborates with Blueprint Medicines_EN